Full Press Release Details
CytoSorbents Provides Preliminary Q2
2020 Financial Results and Corporate Update
Achieved preliminary record total quarterly
revenue of $9.8 million and product sales of $9.5 million, driven by demand for CytoSorb as a treatment of cytokine storm in COVID-19
infection and other illnesses.
N.J., July 20, 2020 - CytoSorbents Corporation (NASDAQ:CTSO), a critical care immunotherapy leader using its CytoSorb
blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, provides
preliminary Q2 2020 financial highlights and a brief corporate update.
Q2 2020 Financial Highlights:
MD, PhD, Chief Executive Officer of CytoSorbents stated, "Sales of CytoSorb increased during Q2 2020 to another quarterly
record, with strength from a solid underlying business in critical care and COVID-19-related sales, that more than offset decreases
in elective cardiac surgeries mandated by hospitals globally. We have treated more than approximately 1,200 COVID-19 patients across
more than 30 countries to date. In India, third behind the U.S. and Brazil in numbers of COVID-19 cases, our partner Biocon recently
announced that CytoSorb has now received approval from the Drugs Controller General of India to treat COVID-19 patients in certain
instances. The COVID-19 pandemic has led to a greater awareness of CytoSorb as a treatment of cytokine storm. This, coupled with
our significantly expanded European sales team, positions us well for expansion of CytoSorb sales for COVID-19 and other core applications
such as sepsis, cardiac surgery, and liver disease."
Dr. Chan continued, "For the REFRESH
2-AKI trial in the U.S., data analysis requested by the Data Safety Monitoring Board (DSMB) is complete, with a committee meeting
scheduled this week. Pending a positive DSMB review and readiness of clinical trial sites, the REFRESH 2-AKI trial may be in a
position to restart this quarter at a number of centers. Meanwhile, full data analysis of the investigator-initiated, 250-patient,
15-center, randomized, controlled REMOVE endocarditis trial is expected in the second half of 2020, with top-line data potentially
Key Accomplishments in Q2 2020:
CytoSorbents plans to host its formal Q2
2020 earnings call on Tuesday, August 4, 2020 after the market close at 4:45PM EDT. Details to follow.
About CytoSorbents Corporation (NASDAQ:
CytoSorbents Corporation is a leader
in critical care immunotherapy, specializing in blood purification. Its flagship product, CytoSorb is approved in the European
Union with distribution in 65 countries around the world, as an extracorporeal cytokine adsorber designed to reduce the "cytokine
storm" or "cytokine release syndrome" that could otherwise cause massive inflammation, organ failure and death in
common critical illnesses. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb
has been used in more than 98,000 human treatments to date. CytoSorb has received CE-Mark label expansions for the removal of bilirubin
(liver disease), myoglobin (trauma) and both ticagrelor and rivaroxaban during cardiothoracic surgery. CytoSorb has also received
FDA Emergency Use Authorization in the United States for use in critically-ill COVID-19 patients with imminent or confirmed respiratory
failure, in defined circumstances. CytoSorb has also been granted FDA Breakthrough Designation for the removal of ticagrelor in
a cardiopulmonary bypass circuit during emergent and urgent cardiothoracic surgery.
CytoSorbents' purification technologies
are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids
by pore capture and surface adsorption. Its technologies have received non-dilutive grant, contract, and other funding of approximately
$33 million from DARPA, the U.S. Army, the U.S. Department of Health and Human Services, the National Institutes of Health (NIH),
National Heart, Lung, and Blood Institute (NHLBI), U.S. Special Operations Command (SOCOM), the U.S. Army, U.S. Special Operations
Command (USSOCOM), the U.S. Air Force, Air Force Material Command (USAF/AFMC) and others. The Company has numerous products under
development based upon this unique blood purification technology protected by many issued U.S. and international patents and multiple
applications pending, including CytoSorb-XL , HemoDefend , VetResQ , K+ontrol , ContrastSorb,
DrugSorb, and others. For more information, please visit the Company's websites at www.cytosorbents.com and www.cytosorb.com
Forward-Looking Statements
This press release includes forward-looking
statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited to, our expectations with respect to our financial performance
for the quarter ended June 30, 2020, the timing and status of our clinical trials, potential commercial opportunities and increased
sales, and other statements about our plans, objectives, representations and contentions and are not historical facts and typically
are identified by use of terms such as "may," "should," "could," "expect," "plan,"
"anticipate," "believe," "estimate," "predict," "potential," "continue"
and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking
statements in this press release, including statements about COVID-19, our expected revenues as a result thereof, represent management's
current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking
statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in
our Annual Report on Form 10-K, filed with the SEC on March 5, 2020, as updated by the risks reported in our Quarterly Reports
on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to
advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon
any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether
as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
The preliminary financial information set
forth herein as of and for the quarter ended June 30, 2020 have been prepared on the basis of currently available information;
however these estimates are preliminary and subject to completion of financial closing procedures that could result in changes
to these amounts. Complete financial results for the quarter ended June 30, 2020 will be included in our Quarterly Report on Form
10-Q for the quarter ended June 30, 2020.
Cytosorbents Contact:
Investor Relations Contact:
U.S. Public Relations Contact:
Eric Kim Rubenstein Public Relations